Drug intelligence / Profile preview

BCM-5011

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BCM-5011 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 (hCD-19), developed by ImmuneCyte Life Sciences for the treatment of B-cell malignancies. The therapy is engineered to recognize and eliminate CD19-positive malignant B cells. BCM-5011 is manufactured using the proprietary CARTXpress™ platform, licensed from ThermoGenesis Holdings, which is designed to streamline production and significantly reduce costs compared to currently approved CAR-T products. It is currently positioned as the lead product candidate in ImmuneCyte's immuno-oncology pipeline.

Other names: BCM-5011BCM5011BCM 5011

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on BCM-5011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM-5011.

Explore the full profile